Ocular Therapeutix Inc (OCUL)
5.75
+0.71
(+14.09%)
USD |
NASDAQ |
Jun 14, 16:00
5.84
+0.09
(+1.57%)
After-Hours: 20:00
Ocular Therapeutix Cash from Financing (Quarterly): 321.22M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 321.22M |
December 31, 2023 | 108.17M |
September 30, 2023 | 51.94M |
June 30, 2023 | 9.645M |
March 31, 2023 | 0.078M |
December 31, 2022 | 0.458M |
September 30, 2022 | 0.374M |
June 30, 2022 | 0.493M |
March 31, 2022 | 0.129M |
December 31, 2021 | 0.667M |
September 30, 2021 | 0.679M |
June 30, 2021 | 2.667M |
March 31, 2021 | -1.162M |
December 31, 2020 | 163.91M |
September 30, 2020 | 0.22M |
June 30, 2020 | 51.06M |
March 31, 2020 | 12.82M |
December 31, 2019 | 9.091M |
September 30, 2019 | 18.61M |
June 30, 2019 | 5.338M |
March 31, 2019 | 42.30M |
December 31, 2018 | 16.33M |
September 30, 2018 | 11.37M |
Date | Value |
---|---|
June 30, 2018 | 6.712M |
March 31, 2018 | 34.23M |
December 31, 2017 | 1.206M |
September 30, 2017 | 1.529M |
June 30, 2017 | 0.796M |
March 31, 2017 | 28.48M |
December 31, 2016 | 0.693M |
September 30, 2016 | 0.078M |
June 30, 2016 | 0.003M |
March 31, 2016 | -0.189M |
December 31, 2015 | 0.308M |
September 30, 2015 | -0.201M |
June 30, 2015 | 65.73M |
March 31, 2015 | -0.137M |
December 31, 2014 | -0.106M |
September 30, 2014 | 67.56M |
June 30, 2014 | 11.95M |
March 31, 2014 | -0.433M |
December 31, 2013 | -0.449M |
September 30, 2013 | -0.454M |
June 30, 2013 | 8.041M |
March 31, 2013 | -0.455M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.162M
Minimum
Mar 2021
321.22M
Maximum
Mar 2024
37.82M
Average
4.002M
Median
Cash from Financing (Quarterly) Benchmarks
Amgen Inc | -1.708B |
EyePoint Pharmaceuticals Inc | 0.115M |
Regeneron Pharmaceuticals Inc | 47.10M |
Agios Pharmaceuticals Inc | 5.864M |
Fate Therapeutics Inc | 95.49M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -33.89M |
Cash from Investing (Quarterly) | -0.255M |
Free Cash Flow | -87.11M |
Free Cash Flow Per Share (Quarterly) | -0.2586 |
Free Cash Flow to Equity (Quarterly) | -25.67M |
Free Cash Flow Yield | -15.72% |